Affimed N.V. (0HL9.L)
| Previous close | 5.28 |
| Open | 5.16 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 5.09 - 5.16 |
| 52-week range | 2.83 - 10.91 |
| Volume | |
| Avg. volume | 722 |
| Market cap | N/A |
| Beta (5Y monthly) | 2.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.66 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Insider MonkeyAffimed N.V. (NASDAQ:AFMD) Upgraded by Laidlaw
We recently compiled the list of the Wall Street Analysts See Upside Potential for 10 Stocks with Rising Price Targets. In this article, we are going to take a look at where Affimed N.V. (NASDAQ:AFMD) stands against the 10 stocks whose price targets were recently raised by analysts. But first, we are going to take […]
Insider MonkeyAffimed N.V. (NASDAQ:AFMD) Q1 2024 Earnings Call Transcript
Affimed N.V. (NASDAQ:AFMD) Q1 2024 Earnings Call Transcript June 12, 2024 Affimed N.V. beats earnings expectations. Reported EPS is $-1.38, expectations were $-1.73. Operator: Good day, everyone and welcome to Affimed’s First Quarter 2024 Earnings and Corporate Update Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer […]
GlobeNewswireAffimed Reports First Quarter 2024 Financial Results & Business Update
- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) - - AFM28 shows single agent efficacy with 2 CR/CRi and 3 stable disease (SD) in 6 patients treated at dose level of 300 mg weekly - Acimtamig (AFM13) combination with AlloNK® (AB-101) natural killer (NK) cells: Recruitment in cohorts 1 and 2 completed. In the first 7 treatment refractory Hodgkin Lymphoma (HL) patients, an ORR of 85.7% observed, wi
